217 related articles for article (PubMed ID: 11469274)
1. Actos (pioglitazone HCL) provides a safe, effective alternative for patients formerly taking Rezulin.
Diabetes Technol Ther; 2000; 2(2):290-1. PubMed ID: 11469274
[No Abstract] [Full Text] [Related]
2. Avandia, a leading alternative for Rezulin patients, prescribed to more than 700,000 patients.
Diabetes Technol Ther; 2000; 2(2):292. PubMed ID: 11469275
[No Abstract] [Full Text] [Related]
3. Warner-Lambert voluntarily withdraws Rezulin.
Diabetes Technol Ther; 2000; 2(2):290. PubMed ID: 11469273
[No Abstract] [Full Text] [Related]
4. New labeling and use changes for Rezulin.
Klonoff DC
Diabetes Technol Ther; 1999; 1(3):350. PubMed ID: 11484719
[No Abstract] [Full Text] [Related]
5. Pioglitazone (Actos).
Med Lett Drugs Ther; 1999 Nov; 41(1066):112. PubMed ID: 10987011
[No Abstract] [Full Text] [Related]
6. Diabetes recall. Though Rezulin's withdrawal is a blow for some patients, there are ways to cope. Here's how.
Gorman C
Time; 2000 Apr; 155(13):94. PubMed ID: 11009709
[No Abstract] [Full Text] [Related]
7. Rezulin to be withdrawn from the market.
Diabetes Technol Ther; 2000; 2(2):289. PubMed ID: 11469272
[No Abstract] [Full Text] [Related]
8. Diabetes drug Rezulin: take it, but take precautions.
Health News; 1999 May; 5(6):7. PubMed ID: 10546576
[No Abstract] [Full Text] [Related]
9. Warner Lambert/Sankyo diabetes drug nears market.
Nat Biotechnol; 1997 Feb; 15(2):113. PubMed ID: 9035120
[No Abstract] [Full Text] [Related]
10. Troglitazone for non-insulin-dependent diabetes mellitus.
Med Lett Drugs Ther; 1997 May; 39(1001):49-51. PubMed ID: 9164446
[No Abstract] [Full Text] [Related]
11. Hepatotoxicity due to troglitazone: report of two cases and review of adverse events reported to the United States Food and Drug Administration.
Kohlroser J; Mathai J; Reichheld J; Banner BF; Bonkovsky HL
Am J Gastroenterol; 2000 Jan; 95(1):272-6. PubMed ID: 10638596
[TBL] [Abstract][Full Text] [Related]
12. Pioglitazone and rosiglitazone for diabetes.
Drug Ther Bull; 2001 Sep; 39(9):65-8. PubMed ID: 11586802
[TBL] [Abstract][Full Text] [Related]
13. [Thiazolidindiones in type II diabetes mellitus].
Bornkessel B
Med Monatsschr Pharm; 1998 Mar; 21(3):66-8. PubMed ID: 9556974
[No Abstract] [Full Text] [Related]
14. Combination therapy in type 2 diabetes: the role of repaglinide.
Moses R
J Assoc Physicians India; 2001 Jan; 49 Spec No():62-8. PubMed ID: 11235608
[No Abstract] [Full Text] [Related]
15. The chase is on (and I'm mad as hell).
Ponte CD
J Am Pharm Assoc (Wash); 2000; 40(4):466. PubMed ID: 10932454
[No Abstract] [Full Text] [Related]
16. NIH opens conflict-of-interest investigation.
Cimons M
Nat Med; 1999 Feb; 5(2):129-30. PubMed ID: 9930847
[No Abstract] [Full Text] [Related]
17. [Meta-analysis shows: insulin sensitizer is safe for the liver].
MMW Fortschr Med; 2002 Oct; 144(40):47. PubMed ID: 12440297
[No Abstract] [Full Text] [Related]
18. Substituting for troglitazone (Rezulin).
Med Lett Drugs Ther; 2000 Apr; 42(1076):36. PubMed ID: 10803176
[No Abstract] [Full Text] [Related]
19. [Clinical efficacy of Pioglitazone (AD-4833)].
Kaneko T; Baba S
Nihon Rinsho; 1997 Nov; 55 Suppl():142-6. PubMed ID: 9434458
[No Abstract] [Full Text] [Related]
20. [Against insulin resistance. Insulin sensitizers].
Verspohl EJ; Weiland F
Pharm Unserer Zeit; 2002; 31(3):280-92. PubMed ID: 12071125
[No Abstract] [Full Text] [Related]
[Next] [New Search]